Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Chugai attributes the success of its development program for the novel interleukin-6 receptor-inhibiting Actemra (tocilizumab) to its partnership with Roche, Chugai Business Development General Manager Kimio Nishimura told Biomedical Asia 2008 attendees in Singapore April 16

You may also be interested in...



Japan's Biennial Price Cuts Spare Innovation But Punish Overachievers

Eisai took the biggest hit in the latest price revisions due to its lead products exceeding peak sales in Japan, according to analysts.

Japan's Biennial Price Cuts Spare Innovation But Punish Overachievers

Eisai took the biggest hit in the latest price revisions due to its lead products exceeding peak sales in Japan, according to analysts.

Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?

Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.

Related Content

UsernamePublicRestriction

Register

SC068218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel